Here, based on our clinical-stage product T3011 backbone (8), we developed an oHSV T7011, delivering dual-blood cancer antigens truncated-CD19 and BCMA on the solid tumor cell surface to promote activation and tumor killing by CD19-specific CAR T (CAR-TCD19) and BCMA-specific CAR T (CAR-TBCMA) cells. This evidence concerns the gene CD19 and hematopoietic and lymphoid system neoplasm.